From WikiProjectMed
Jump to navigation Jump to search
Trade namesNorpace, Rythmodan, others
  • (RS)-4-(Diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide
Clinical data
Drug classClass 1a anti-arrhythmic[1]
Main usesPrevention of ventricular tachycardia[1]
Side effectsDry mouth, constipation, blurry vision, urinary retention, nausea, tiredness, dizziness[1]
  • AU: B2
  • US: C (Risk not ruled out)
Routes of
By mouth
External links
Legal status
Protein binding50% to 65%
MetabolismLiver (CYP3A4-mediated)
Elimination half-life6.7 hours (range 4 to 10 hours)
ExcretionKidney (80%)
Chemical and physical data
Molar mass339.483 g·mol−1
3D model (JSmol)
Melting point94.5 to 95 °C (202.1 to 203.0 °F)
  • O=C(N)C(c1ncccc1)(c2ccccc2)CCN(C(C)C)C(C)C
  • InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25) checkY

Disopyramide, sold under the brand names Norpace among others, is a medication used to prevent ventricular tachycardia.[1] It is typically only used when other medications are not effective.[1] Use is not recommended for less serious arrhythmias.[1] It is taken by mouth.[1]

Common side effects include dry mouth, constipation, blurry vision, urinary retention, nausea, tiredness, and dizziness.[1] Other side effects may include heart failure, arrhythmias, and low blood sugar.[1] Safety in pregnancy is unclear.[1] It is a class 1a anti-arrhythmic and sodium channel blocker.[1] It has a negative effect on the hearts ability to contract.[1]

Disopyramide was approved for medical use in the United States in 1977.[1] It is available as a generic medication.[2] In the United Kingdom 84 pills of 100 mg costs the NHS about £27 as of 2021.[2] In the United States this amount costs about 55 USD.[3]

Medical use

Hypertrophic cardiomyopathy (HCM) often presents with left ventricular (LV) intracavitary obstruction due to systolic anterior motion of the mitral valve, and mitral-septal contact, diagnosed readily with echocardiography. Negative inotropic drugs are first-line therapy. Beta-blockers are used first, and while they improve symptoms of shortness of breath, chest pain and exercise intolerance, they do not reduce resting LV intraventricular pressure gradients and often are inadequate to control symptoms. Disopyramide controlled release is the most potent agent available for reducing resting pressure gradients and improving symptoms.[4][5][6][7] Disopyramide has been actively used for more than 30 years.[8] Disopyramide administration for obstructive HCM has a IIa recommendation in the 2011 American Heart Association/American College of Cardiology Foundation guidelines for treatment of obstructive HCM.[9] A IIa treatment recommendation indicates that benefits outweigh risk, and that it is reasonable to administer treatment.

Negative inotropes improve LV obstruction by decreasing LV ejection acceleration and hydrodynamic forces on the mitral valve. Disopyramide's particular efficacy is due to its potent negative inotropic effects; in head-to-head comparison, it is more effective for gradient reduction than either beta-blocker or verapamil.[10] Disopyramide is most often administered with beta-blockade. When used in patients resistant to beta-blockade, disopyramide is effective in 60% of cases, reducing symptoms and gradient to the extent that invasive procedures such as surgical septal myectomy are not required.[7]

Disopyramide, despite its efficacy, has one main side effect that has limited its use in the US, though it has seen wider application in Canada, UK and Japan. Vagal blockade predictably causes dry mouth, and in men with prostatism, may cause urinary retention. Teichman et al. showed that pyridostigmine used in combination with disopyramide substantially alleviates vagolytic side effects without compromising antiarrhythmic efficacy.[11] This combination has also been shown to be effective and safe in obstructive HCM in a large cohort of patients.[7] Some clinicians prescribe pyridostigmine sustained release (marketed in the US as Mestinon Timespan) to every patient begun on disopyramide.[12] This combination increases acceptance of higher disopyramide dosing, important since there is a dose-response correlation in obstructive HCM, higher doses yielding lower gradients.

Another concern about disopyramide has been the hypothetical potential for inducing sudden death from its type 1 anti-arrhythmic effects. However, a multicenter registry and two recent cohort registries have largely reduced this concern, by showing sudden death rates lower than that observed from the disease itself.[4][5][7]

These concerns about the drug must be viewed from the clinical perspective that disopyramide is generally the last agent that is tried for patients before they are referred for invasive septal reduction with surgical septal myectomy (an open-heart operation) or alcohol septal ablation (a controlled heart attack). Both of these invasive procedures have risk of morbidity and mortality.

For selected patients, a trial of oral disopyramide is a reasonable approach before proceeding to invasive septal reduction. Patients who respond to disopyramide are continued on the drug. Those who continue to have disabling symptoms or who experience side effects are promptly referred for septal reduction. Using such a stepped strategy, investigators have reported that survival does not differ from that observed in the age-matched normal United States population.[7]

Side effects

  • Acute heart failure – Disopyramide should not be given to patients with impaired LV systolic function and low ejection fraction. Heart failure is not seen when disopyramide is used in patients with normal or supernormal LV systolic function.
  • Severe hypotension – Disopyramide should not be given to patients with impaired LV systolic function and low ejection fraction. Hypotension is not seen in patients with normal or supernormal LV systolic function.

Atropine like effects (anticholinergic)[13]

Additionally, disopyramide may enhance the hypoglycaemic effect of gliclazide, insulin, and metformin.

Mechanism of action

Disopyramide's Class 1a activity is similar to that of quinidine in that it targets sodium channels to inhibit conduction.[14][15] Disopyramide depresses the increase in sodium permeability of the cardiac myocyte during Phase 0 of the cardiac action potential, in turn decreasing the inward sodium current. This results in an increased threshold for excitation and a decreased upstroke velocity.[14] Disopyramide prolongs the PR interval by lengthening both the QRS and P wave duration.[15] This effect is particularly well suited in the treatment of ventricular tachycardia as it slows the action potential propagation through the atria to the ventricles. Disopyramide does not act as a blocking agent for beta or alpha adrenergic receptors, but does have a significant negative inotropic effect on the ventricular myocardium.[16] As a result, the use of disopyramide may reduce contractile force up to 42% at low doses and up to 100% in higher doses leading to heart failure.[15]

Levites proposed a possible secondary mode of action for disopyramide, against reentrant arrhythmias after an ischemic insult. Disopyramide decreases the inhomogeneity between infarcted and normal myocardium refractory periods; in addition to lengthening the refractory period.[17] This decreases the chance of re-entry depolarization, because signals are more likely to encounter tissue in a refractory state which cannot be excited.[18] This provides a possible treatment for atrial and ventricular fibrillation, as it restores pacemaker control of the tissue to the SA and AV nodes.[19]

See also


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 "Disopyramide Monograph for Professionals". Drugs.com. Archived from the original on 17 January 2021. Retrieved 26 December 2021.
  2. 2.0 2.1 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 110. ISBN 978-0857114105.
  3. "Disopyramide Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 26 December 2021.
  4. 4.0 4.1 Ball W, Ivanov J, Rakowski H, Wigle ED, Linghorne M, Ralph-Edwards A, Williams WG, Schwartz L, Guttman A, Woo A (2011). "Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment". J Am Coll Cardiol. 58: 2313–2321. doi:10.1016/j.jacc.2011.08.040.
  5. 5.0 5.1 Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ (2005). "Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy". J Am Coll Cardiol. 45 (8): 1251–1258. doi:10.1016/j.jacc.2005.01.012. PMID 15837258.
  6. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, Tome Esteban MT, McKenna WJ (2006). "Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy". Heart. 92 (6): 785–791. doi:10.1136/hrt.2005.068577. PMC 1860645. PMID 16216855.
  7. 7.0 7.1 7.2 7.3 7.4 Sherrid, M. V.; Shetty, A; Winson, G; Kim, B; Musat, D; Alviar, C. L.; Homel, P; Balaram, S. K.; Swistel, D. G. (2013). "Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil". Circulation: Heart Failure. 6 (4): 694–702. doi:10.1161/CIRCHEARTFAILURE.112.000122. PMID 23704138.
  8. Pollick C (1982). "Muscular subaortic stenosis: Hemodynamic and clinical improvement after disopyramide". N Engl J Med. 307 (16): 997–999. doi:10.1056/nejm198210143071607.
  9. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011). "accf/aha guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". J Am Coll Cardiol. 58 (25): e212–260. doi:10.1016/j.jacc.2011.06.011. PMID 22075469.
  10. Kajimoto K, Imai T, Minami Y, Kasanuki H. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline. Am J Cardiol. 2010;106:1307-1312
  11. Teichman SL, Ferrick A, Kim SG, Matos JA, Waspe LE, Fisher JD (1987). "Disopyramide-pyridostigmine interaction: Selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect". J Am Coll Cardiol. 10 (3): 633–641. doi:10.1016/s0735-1097(87)80207-3.
  12. Sherrid MV, Arabadjian M. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2012;54:483-492
  13. Rang and Dale's pharmacology
  14. 14.0 14.1 Kim, S. Y.; Benowitz, N. L. (1990). "Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide". Drug Safety. 5 (6): 393–420. doi:10.2165/00002018-199005060-00002. PMID 2285495.
  15. 15.0 15.1 15.2 Mathur, P. P. (1972). "Cardiovascular effects of a newer antiarrhythmic agent, disopyramide phosphate". American Heart Journal. 84 (6): 764–70. doi:10.1016/0002-8703(72)90069-5. PMID 4150336.
  16. Hulting J, Rosenhamer G: Hemodynamic and electrocardiographic effects of disopyramide in patients with ventricular arrhythmia. Acta Med Scand 199:41-51, 1976.
  17. Levites, R; Anderson, G. J. (1979). "Electrophysiological effects of disopyramide phosphate during experimental myocardial ischemia". American Heart Journal. 98 (3): 339–44. doi:10.1016/0002-8703(79)90046-2. PMID 474380.
  18. Guyton, Arthur C., Hall, John E. (2006). Textbook of Medical Physiology (11th ed.). Philadelphia: Elsevier Saunders.
  19. Katzung, Bertram G., Masters, Susan B., Trevor, Anthony J. (2009). Basic and Clinical Pharmacology (11th ed.). New York: McGraw Hill

External links